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INTRODUCTION
Obstructive sleep apnea (OSA) is a highly prevalent disorder, 
affecting at least 4% of adult males and 2% of adult females, and 
is a well-established independent risk factor for cardiovascular 
disease and associated morbidity and mortality.1 Emerging ev-
idence from both animal and human studies links OSA with 
increased cancer incidence and worse cancer outcomes.2–5 Epi-
demiological data from North America and Europe suggest ma-
lignancy is more likely to occur in subjects with severe sleep 
disordered breathing,3,4 while animal models suggest that in-
termittent hypoxia may promote tumor progression and metas-
tasis.6,7 The mechanisms underlying these adverse outcomes in 
OSA are poorly understood, but chronic systemic inflammation, 
oxidative stress, and immune dysfunction have been postulated 
as potential contributory factors. However, to date there have 
been few if any clinical studies specifically evaluating potential 
pro-oncogenic factors in OSA cohorts.
Invariant natural killer T (iNKT) cells are a rare population 
of human innate T cells with an established role in cancer bi-
ology and other conditions such as autoimmune diseases.8 They 
express the invariant T cell receptor (TCR) Vα24Jα18 chain and 
NK-like surface molecules9 and are potent immunomodulatory 
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cells capable of simultaneously secreting both TH1 and TH2 
cytokines upon stimulation.10,11 Following stimulation, iNKT 
cells can also activate other cells of the innate and adaptive 
immune system.12 Studies of in vitro and animal models have 
demonstrated the ability of iNKT cells to direct anti-cancer 
responses in the prevention of tumors and in the eradication of 
existing tumors,13 while they have also been shown to directly 
lyse tumor cells.14 Furthermore, the number and function of 
circulating iNKT cells are reduced in cancer patients,8,15,16 and 
therapeutic strategies aimed at restoring iNKT cell number 
and function have shown significant promise in the context of 
cancer immunotherapy.17–21
To date there are no studies evaluating the relationship be-
tween OSA and iNKT cells, and in particular evaluating how 
OSA severity and burden of nocturnal hypoxemia may affect 
their number and function. In this study, we evaluate the fre-
quency of circulating iNKT cells in participants with OSA, 
the effect of nocturnal continuous positive airway pressure 
(nCPAP) therapy on their number, and the effect of hypoxia on 
iNKT cell function.
METHODS
Participants
The study was approved by the ethics committee at St Vin-
cent’s University Hospital, Dublin, and was performed in 
accordance with the declaration of Helsinki. Male snorers re-
ferred to sleep clinic for assessment of suspected sleep disor-
dered breathing, with no history of hypertension, dyslipidemia, 
or cardiovascular disease, and were non-smokers and taking 
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no regular medications, were enrolled in the study after written 
informed consent. All subjects underwent inpatient polysom-
nography, performed and scored according to the 2007 AASM 
criteria,22 with the presence and severity of sleep disordered 
breathing classified according to the apnea-hypopnea index 
(AHI). An apnea was scored in the presence of ≥ 90% reduc-
tion in airflow of ≥ 10 sec duration. A hypopnea was scored 
when airflow was reduced by ≥ 30% in combination with 4% 
oxyhemoglobin desaturation from pre-event baseline, or when 
airflow was reduced by ≥ 50% in combination with an arousal 
from sleep. Subjects with moderate-severe OSA were com-
menced on nocturnal CPAP as clinically indicated, following 
an overnight, inpatient dose-titration study. Blood samples in 
the fasting state (at 08:00) were obtained for isolation of pe-
ripheral blood mononuclear cells (PBMCs).
Preparation of PBMCs
Ten mL of venous blood was collected in heparinized blood 
collection tubes and PBMCs were isolated by density centrifu-
gation on Lymphoprep (Nycomed, Norway) at 400 g for 25 
minutes. Cells were washed twice in Hank Buffered Salt So-
lution (HBSS), and the resulting cell pellet was suspended in 
1 mL of complete RPMI 1640 medium for determination of 
cell count and viability by ethidium bromide/acridine orange 
staining. The frequency of circulating iNKT cells was evalu-
ated using the combination of monoclonal antibodies (mAbs) 
6b11 PE and CD3 APC by flow cytometry.
Generation of iNKT Cell Lines
PBMCs from healthy controls were used to generate iNKT 
cell lines by positive selection using anti-6b11 magnetic beads 
(Miltenyi Biotech, UK) as per the manufacturer’s instructions. 
The purified iNKT cells were stained with 6b11 FITC and CD3 
PE-Cy5 mAbs (BD Bioscience, UK) for 30 min and washed 
with phosphate buffered saline with azide (PBA). Double posi-
tive cells (CD3 and 6b11) were then sorted using fluorescence-
activated cell sorting (FACS) Aria cell sorter (BD Biosciences). 
One thousand purified iNKT cells per well were plated in a 
round bottom 96-well plate with 150,000 irradiated PBMCs 
from 2 donors as feeders, 10 ng/mL of phytohemagglutinin 
(PHA) (Sigma Aldrich, UK) and 250 U/mL of interleukin-2 
(IL-2) (Miltenyi Biotec). The PHA was diluted over 48 h using 
IL-2 supplemented complete RPMI 1640. The media was then 
replenished twice weekly and wells divided as required during 
growth. Mature iNKT cells were used for cytotoxicity and 
apoptosis experiments.
Flow Cytometric Staining and Analysis
PBMCs obtained from participants were stained with mono-
clonal antibodies (mAbs) against CD3, 6b11, CD8, CD4, CD56, 
and vα24. Stained cells were then acquired with FACS Calibur 
flow cytometer (BD Biosciences, NJ, USA) and analyzed with 
Cell Quest Pro (BD Biosciences). Invariant NKT cell numbers 
are expressed as percentage of lymphocytes.
Hypoxia Experiment
Invariant NKT cells (200,000 cells per well in triplicate) were 
incubated in a hypoxia chamber at 1% oxygen and 5% carbon 
dioxide, or incubated in normoxic conditions in an incubator 
containing 21% oxygen and 5% carbon dioxide at 37°C for 24 
hours. The percentage of apoptotic cells compared to cells ex-
posed to normoxia for 24 h was determined by flow cytometry 
using Annexin V apoptosis kit as per manufacturer’s instruc-
tions (Milteny Biotech, Germany). Cell viability was checked 
by ethidium bromide/acridine orange staining, and equal num-
bers of viable cells were used for cytotoxicity studies. We as-
sessed the effect of 24-h hypoxia on the ability of iNKT cells 
to lyse tumor cells by co-culturing hypoxic or normoxic iNKT 
cells with CD1d transfected C1R tumor cells at a ratio of 5:1 
(effector to target ratio), and the proportion of lysed tumor cells 
expressed in arbitrary units were measured using the CytoTox-
Fluor assay (Promega, UK). Cell supernatants harvested after 
culturing iNKT cells in hypoxia or normoxia with or without 
TCR stimulation (anti-CD3/28 stimulation beads (Miltenyi 
Biotech, Germany), were analyzed for cytokine levels (TNF-α 
and IL-4, classically produced simultaneously by iNKT cells) 
by Enzyme-linked immunosorbent assay (ELISA) (R&D Sys-
tems, USA) in triplicates.
Statistical Analysis
Statistical analysis was performed using Prism version 5b 
software (GraphPad Software, San Diego, CA, USA). Data are 
presented as mean ± SEM and median ± interquartile range 
as appropriate. Groups were compared using ANOVA, stu-
dent t-test or Mann-Whitney U test as appropriate. Correla-
tion coefficients were generated to examine the relationship of 
iNKT cell numbers with indices of OSA severity and obesity. 
A P value < 0.05 was considered statistically significant.
RESULTS
A total of 33 patients were enrolled. Table 1 shows the base-
line characteristics of the participants grouped according to 
OSA severity: no OSA (AHI < 5), mild-moderate OSA (AHI 
5–30) and severe OSA (AHI > 30). Systolic blood pressure 
levels and subjective daytime sleepiness increased with in-
creasing OSA severity, but no significant differences in demo-
graphic, anthropometric, or other clinico-metabolic variables 
were observed between the groups, except for LDL which was 
highest in the severe OSA group probably representing a car-
diovascular risk marker in severe OSA.
Participants with Severe OSA Have Low Frequency of 
Circulating iNKT Cells
The frequency of circulating iNKT cells was significantly 
lower in participants with AHI > 30 (mean 0.18% ± 0.06%) 
compared to patients with AHI 5–30 (mean 0.24% ± 0.08%) 
and < 5 (mean 0.35% ± 0.11%), P = 0.0026 (Figure 1A). There 
was no significant difference in the frequency of other lym-
phocyte subpopulations (Table 1). The frequency of iNKT 
cells correlated inversely with OSA severity as measured by 
apnea hypopnea index (AHI) (r = −0.54, P = 0.001; Figure 1B), 
oxygen desaturation index (ODI) (r = −0.58, P = 0.0003; 
Figure 1C), and percentage of sleep time with SpO2 < 90% 
(r = −0.54, P = 0.005, Figure 1D). There was no significant cor-
relation with BMI (r = −0.31, P = 0.08, Figure 1E), and despite 
significant difference in LDL between the groups, there was 
no correlation between the frequency of iNKT cells and LDL 
(r = −0.033, P = 0.85).
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Table 1—Participant characteristics by OSA severity.
Total Cohort No OSA Mild-Moderate OSA Severe OSA P value*
n 33 9 12 12
Age 43.7 (10.2) 40.9 (8.6) 46.7 (12.7) 42.9 (8.4) 0.42
BMI (kg/m2) 31.9 (6.3) 29.3 (5.2) 32.7 (8.0) 33.1 (4.9) 0.35
Waist circumference (cm) 107.4 (16.5) 99.2 (14.1) 110.3 (20.0) 111.7 (12.4) 0.20
Neck circumference (cm) 42.6 (3.7) 41.1 (4.6) 42.6 (3.2) 44.1 (3.0) 0.22
SBP (mm Hg) 140.6 (16.9) 130.3 (3.6) 138.0 (21.3) 149.6 (13.6) 0.04
DBP (mm Hg) 82.9 (15.5) 81.1 (5.3) 81.9 (6.9) 84.9 (24.1) 0.86
AHI (events/h) 27.9 (27.3) 2.1 (1.8) 18.4 (7.4) 56.7 (23.9) 0.01
ODI (events/h) 23.3 (26.5) 1.4 (1.3) 14.7 (5.7) 50.8 (28.2) 0.01
ESS score 10.7 (5.6) 6.7 (4.5) 11.1 (6.0) 13.3 (4.5) 0.02
HOMA-IR 3.89 (2.68) 2.91 (1.71) 3.53 (2.29) 4.98 (3.37) 0.19
HbA1c (%) 5.59 (0.47) 5.44 (0.70) 5.63 (0.42) 5.67 (0.28) 0.55
Cholesterol (mmol/L) 4.77 (0.82) 4.94 (0.89) 4.43 (0.88) 5.00 (0.60) 0.19
HDL-Cholesterol (mmol/L) 1.12 (0.33) 1.13 (0.24) 1.25 (0.44) 0.98 (0.18) 0.15
LDL-Cholesterol (mmol/L) 2.96 (0.78) 3.14 (0.74) 2.50 (0.81) 3.30 (0.55) 0.03
Absolute lymphocytes (x109/L) 2.92 (0.56) 2.88 (0.50) 2.68 (0.53) 0.10
T cells (% Lymphocytes) 79.19 (1.97) 80.62 (2.17) 78.24 (3.15) 0.15
CD4+ T Cells (% Lymphocytes) 45.56 (2.08) 47.15 (3.12) 49.43 (1.89) 0.26
CD8+ T Cells (% Lymphocytes) 10.33 (1.51) 9.89 (1.37) 9.71 (1.36) 0.51
iNK Cells (% Lymphocytes) 7.45 (1.54) 6.43 (1.26) 6.16 (0.87) 0.14
*Comparisons made using one-way analysis of variance. AHI, apnea-hypopnea index; BMI, body mass index; DBP, diastolic blood pressure; ESS, Epworth 
Sleepiness Score; ODI, oxygen desaturation index; OSA, obstructive sleep apnea; SBP, systolic blood pressure.
Figure 1—iNKT cell number and associations in OSA. (A) iNKT cell number according to sleep severity, comparisons made using Kruskal-Wallis test. 
(B-E) Correlation of iNKT cells with sleep severity (AHI), oxygen desaturation index (ODI), and % SpO2 < 90. **P < 0.01, comparisons made using 
spearman correlation coefficient. All analysis were performed in 33 patients apart from panel D.
**A
D E
B C
D
ow
nloaded from
 https://academ
ic.oup.com
/sleep/article-abstract/38/10/1629/2468605 by guest on 10 February 2020
SLEEP, Vol. 38, No. 10, 2015 1632 iNKT Cells in OSA—Gaoatswe et al.
Circulating iNKT Cells Increase in Participants with Severe 
OSA after CPAP Therapy.
We prospectively followed up 10 participants with severe 
OSA who underwent treatment with nocturnal continuous pos-
itive airway pressure (nCPAP) and found a significant increase 
in the frequency of circulating iNKT cells following 12 months 
of therapy (mean 0.19% ± 0.06% vs 0.25% ± 0.10%, P = 0.015; 
Figure 2). When the change in iNKT cell number was assessed 
according to compliance, this did not reach statistical signifi-
cance, P = 0.90, probably due to small numbers in each group.
Exposure of iNKT Cells to Hypoxia Leads to Apoptosis and 
Impaired Cytotoxicity
Primary iNKT cell lines were used to study the in vitro 
effects of hypoxia on iNKT cell phenotype and function. In-
variant NKT cells were exposed to 1% oxygen for 24 h and 
the percentage of apoptotic cells compared to cells exposed to 
normoxia for 24 hours. Significantly more iNKT cells exposed 
to hypoxia underwent apoptosis compared to cells exposed to 
normoxia (3.44% [1.90–4.16] vs 0.82% [0.75–1.69], P = 0.016, 
Figure 3A).
We also assessed the effect of 24-h hypoxia on the ability 
of iNKT cells to lyse CD1d transfected C1R tumor cells in a 
co-culture model. Invariant NKT cells exposed to hypoxia 
lysed fewer CD1d tumor cells compared to cells exposed to 
normoxia (3232 [2435–3590] vs 2757 [851–3159], P = 0.035, 
Figure 3B). Cell supernatants were interrogated for cytokine 
production by ELISA and there was no difference in cytokine 
levels (TNF-α and IL-4) between cells exposed to hypoxia and 
normoxia (Figures 3C, 3D).
DISCUSSION
The association between cancer and OSA is an emerging 
field, as yet unsupported by the wealth of evidence linking sleep 
disordered breathing with excess cardiometabolic morbidity 
and mortality.23 However, epidemiological data from Europe 
and North America are certainly suggestive of an important 
potential relationship between OSA and malignancy. Among 
1,522 community-based subjects enrolled in the Wisconsin 
Sleep Cohort, severe sleep disordered breathing was associ-
ated with an almost five-fold risk of cancer death.3 Similarly, 
in a cohort of nearly 5,000 Spanish patients attending sleep 
clinics, severity of nocturnal hypoxemia predicted incident 
cancer even following rigorous adjustment for confounding 
variables.4 Data from animal models has shown that exposure 
to intermittent hypoxia may increase tumor progression, and 
appears to promote tumor metastasis.2,7
A number of potential contributory mechanistic factors have 
been suggested as mediators of this effect. A large body of lit-
erature has shown that OSA and associated intermittent hypox-
emia lead to chronic systemic inflammation,24 a pro-oncogenic 
state.25 OSA is also now recognized as an oxidative stress dis-
order,26 with the generation of reactive oxygen species by sleep 
disordered breathing possibly increasing cancer risk. Mean-
while hypoxia, via stabilization of hypoxia-inducible factor, 
has an established role in promoting tumor angiogenesis, 
Figure 2—Effect of CPAP on iNKT frequency. iNKT cell frequency 
was assessed following 12 months of CPAP therapy and compared to 
baseline levels for each subject. *P < 0.05, comparisons made by paired 
t-test.
*
Figure 3—Effects of hypoxia on iNKT cell function. (A) Exposure of iNKT cells to hypoxia leads to apoptosis; comparisons made by paired t test. 
(B) Exposure of iNKT cells to hypoxia leads to reduced cytotoxicity to CD1d cells; comparisons made by paired t test. (C,D) Hypoxia has no effect on 
TNF-α and IL-4 production by iNKT cells, comparisons between unstimulated iNKTs exposed to normoxia versus hypoxia and stimulated iNKTs exposed 
to normoxia versus hypoxia. *P < 0.05.
*
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proliferation, and survival.27 However, to date there have been 
few data specifically exploring potential mechanisms in OSA 
patients.
Invariant NKT cells are of established importance in cancer 
biology. They constitute a rare subset of human innate T 
cells, and are potent drivers of innate and acquired immune 
responses, capable of driving anti-inflammatory Th2-type, 
regulatory T cell-type and pro-inflammatory Th1-type im-
mune responses.11 Data from in vitro and rodent models have 
demonstrated the ability of iNKT cells to direct anti-tumor re-
sponses and to directly lyse tumor cells.13,28 In patients with a 
variety of advanced cancers, circulating iNKT cell numbers 
have been shown to be markedly reduced compared to healthy 
controls, and may also have impaired anti-tumor function.15,29 
Moreover, a low frequency of circulating iNKT cells predicts a 
worse prognosis in subjects with head and neck squamous cell 
carcinoma.8,30 Our group has previously shown pro-oncogenic 
conditions such as smoking and obesity to be associated with 
depletion of iNKT cells.16,31 Meanwhile, a number of phase I/II 
clinical trials have suggested that augmentation of iNKT cell 
numbers and functionality may lead to improved outcomes in 
patients with advanced malignancy.20,32
In this first study of iNKT cells in subjects with OSA, we 
show that the frequency of circulating iNKT cells is reduced 
in patients with severe OSA, and that their numbers correlate 
inversely with AHI and the severity of nocturnal hypoxemia as 
measured by ODI and SpO2 < 90%. Furthermore, successful 
treatment with nCPAP appears to partially abrogate this reduc-
tion. A potential role for hypoxemia and associated tissue hy-
poxia in driving this observation is suggested by the increase 
in iNKT cell apoptosis following prolonged exposure to sus-
tained hypoxia. Moreover, hypoxia appears to alter iNKT cell 
function, impairing their ability to lyse tumor cells, although 
cytokine production is not affected, which may be due to the 
differential effect of hypoxia on iNKT cells. Together these 
findings suggest that the presence of significant sleep disor-
dered breathing may hinder an important innate anti-cancer 
defence mechanism. Indeed, previous work has shown that 
hypoxia impairs iNKT cell function with hypoxia leading to 
reduction of cytotoxicity, iNKT cell viability, and impaired in-
terferon gamma secretion.33
Our study has a number of important limitations. First, while 
we observed an increase in iNKT cell numbers following suc-
cessful treatment with nCPAP, we did not employ an nCPAP 
withdrawal model or include a sham nCPAP control group. 
However, the striking correlation between indices of OSA se-
verity and frequency of circulating iNKT cells in parallel with 
a beneficial effect from appropriate therapy is suggestive of 
a potential causative effect. Second, our cohort was not nec-
essarily typical of the standard sleep clinic population, being 
comprised of male nonsmokers without significant cardio-
metabolic comorbidity. Finally, our in vitro model of sustained 
hypoxia does not mimic the cyclical intermittent hypoxemia 
seen in patients with sleep disordered breathing, and conse-
quently does not replicate the environment of circulating iNKT 
cells in OSA patients. Additional experiments exposing iNKT 
cells to intermittent hypoxia were not feasible in our in vitro 
model, as the iNKT cell lines are maintained in suspension. 
However, only a small proportion of iNKT cells are located 
in the circulation, with the bulk being distributed throughout 
other tissues, most notably omental fat,16 and previous studies 
have shown that iNKT cells migrate to tumor microenviron-
ment to interact with other immune cells.33 Recent data from 
rodent models suggest that—particularly in obese animals—
exposure to intermittent hypoxia with consequent intermittent 
hypoxemia can translate into a profile of sustained hypoxia at 
a tissue level.34 Similarly, although our model utilized a com-
paratively severe degree of hypoxia, prior in vivo studies have 
measured oxygen tensions to be as low as 0.5% in murine lym-
phoid organs.35 While we are unaware of any comparable data 
from human studies, it can be speculated that oxygen tension 
might fall to these low levels in the lymphoid organs of OSA 
patients as they experience repeated cycles of apnea
In summary, we report a low frequency of circulating iNKT 
cells in patients with severe OSA, a relationship that is partially 
remediable with successful nCPAP therapy, while hypoxia ap-
pears to significantly inhibit the ability of iNKT cells to eradi-
cate cancer cells. Further studies are required to longitudinally 
evaluate the contribution of low frequency of circulating iNKT 
cells to adverse cancer outcomes in OSA populations, and to 
further assess the impact of nCPAP therapy on their number 
and function.
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